Navigation Links
Delcath Systems Announces the Sale of 5,185,000 Shares of Common Stock
Date:8/16/2010

the solicitation of an offer to buy, any of the securities, nor shall there be any sale of these securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About Delcath Systems

Delcath Systems, Inc. is a development stage, specialty pharmaceutical and medical device company focused on oncology.  Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents.  The Company's initial focus is on the treatment of primary and metastatic liver cancers.  Delcath recently concluded a Phase III metastatic melanoma study, and the Company is currently conducting a multi-arm Phase II trial to treat other liver cancers. The Company has not yet received FDA or any foreign regulatory approval for commercial sale of its system.  For more information, please visit the Company's website at www.delcath.com.  

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to the acceptability of the Phase III clinical trial data by the FDA, our ability to successfully complete an FDA new drug application, acceptance of the new drug application by the FDA, approval by the FDA or other regulatory authorities of the current or future drug delivery system for the treatment of metastatic melanoma, our ability
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Delcath Highlights Phase III Trial Results Presented at ASCO
2. Delcath Systems Names Michael D. Dellario as Vice President, Global Marketing
3. Eamonn Hobbs Appointed President & CEO of Delcath Systems, Inc.
4. Delcath Systems Receives Preliminary Notification of Inclusion in Russell 3000(R) Index
5. Delcath Enters Agreement to Sell 869,565 Units
6. Delcath Systems Granted Third Orphan Drug Designation
7. Eric D. Whitman, MD to Present on the Delcath PHP System(TM) at the 7th World Congress on Melanoma
8. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point
9. Delcath Adds Senior Pharmaceutical Professional to Its Board of Directors
10. Jonathan Lewis, M.D., Ph.D. Steps Down From Delcath Systems Board of Directors
11. Delcath Adds University of Pittsburgh Medical Center to Phase III Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Switzerland (PRWEB) , ... August 27, 2015 , ... ... on customers’ weighing needs and expertly narrows down the product choices to a ... selection criteria pares down the list to models that fit best with the ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... presented new data on the relationship of genetics and hypertension at the ... Heart Disease in Vancouver, British Columbia, Canada. The event, which boasts an extensive ...
(Date:8/26/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... quarter ended June 30, 2015. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... Oral Amp B program, rapidly advancing towards the ... Rae , President & CEO of iCo Therapeutics. "We ...
(Date:8/26/2015)... ... August 26, 2015 , ... ... investment in the development and manufacture of highly valued cardiac markers used in ... team's extensive expertise with protein chemistry has led to the development and commercialization ...
Breaking Biology Technology:METTLER TOLEDO Updates Online Scale Selection Tool 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2
... CLEVELAND, Ohio, June 2 Simbionix has announced ... its LAP Mentor simulator that,gives trainees hands-on experience ... of ectopic pregnancy, tubal,sterilization and oophorectomy., The ... suite of laparoscopic,procedures developed for the LAP Mentor, ...
... Clinical Oncology Proves Accurate, Measurement of ER and PR ... ... June 2 Genomic Health,Inc. (Nasdaq: GHDX ) today ... a study confirming RT-PCR by Oncotype DX can,deliver quantitative gene ...
... June 2 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. (TSX-V:,QPT), ... 12-patient,Phase I clinical study entitled "ACP-SL017 Topical Gel: ... Actinic Keratosis" has met both its primary and,exploratory ... for the first time, clinical,validation for our SonoLight ...
Cached Biology Technology:Simbionix Takes Non-Invasive GYN Surgical Training to the Next Level 2Genomic Health Announces Expansion of Oncotype DX(R) Breast Cancer Test to Include Quantitative Estrogen Receptor (ER) and Progesterone Receptor (PR) Scores 2Genomic Health Announces Expansion of Oncotype DX(R) Breast Cancer Test to Include Quantitative Estrogen Receptor (ER) and Progesterone Receptor (PR) Scores 3Genomic Health Announces Expansion of Oncotype DX(R) Breast Cancer Test to Include Quantitative Estrogen Receptor (ER) and Progesterone Receptor (PR) Scores 4Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis 2Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis 3
(Date:8/6/2015)... , Aug. 6, 2015  Today, U.S. ... visit Crossmatch ™ to learn firsthand how ... protect data. Crossmatch is a world leader in ... and expertise are helping federal agencies and commercial ... security.   "The vast majority of ...
(Date:8/5/2015)... CHICAGO , August 5, 2015 ... Identity & Access Management Market by Software, Services, Vertical (BFSI, ... Chemical/Pharma), & Geography - Global Forecast to 2020", published ... Access Management Market globally into various segments. The global ... in 2014 to $546.2 Million by 2019, at a ...
(Date:8/4/2015)... , Aug. 04, 2015 ... ) has announced the addition of the ... Software, and Service), Sub-Segment (Computer Forensics, Network ... Tool Types, Service, Vertical and Region - ... their offering. By Component (Hardware, ...
Breaking Biology News(10 mins):Rep. Honda to Visit Crossmatch in Redwood City 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
... One of the smallest parts of the brain is getting ... crucial role in decision making. A University of British ... the lateral habenula, a region of the brain linked to ... be integral in cost-benefit decisions. "These findings clarify the ...
... -- Many owl species have developed specialized plumage to effectively ... to hunt and capture their prey in silence. ... how owls achieve this acoustic stealth will present their findings ... meeting, held Nov. 24 26, in Pittsburgh, Pa. -- ...
... Greenland,s ice sheet is small today? It was smaller ... from 3-5,000 years ago, according to scientists who studied the ice ... Arctic fossil record. "What,s really interesting about this is that ... ago, maybe as late as 4,000 years ago. The oceans, on ...
Cached Biology News:Scientists find brain region that helps you make up your mind 2The secrets of owls' near noiseless wings 2Greenland's shrunken ice sheet: We've been here before 2Greenland's shrunken ice sheet: We've been here before 3
CleanBox DNA workstation with two 254nm UV lambs & 12-hr timer, 90cm (36-inch)width, single door, 115V (w/crating)...
Mouse polyclonal antibody raised against a partial recombinant DDEF2. NCBI Entrez Gene ID = 8853...
Mouse polyclonal antibody to BAG2 - BCL2-associated athanogene 2...
... multi-functional mixing devices. Stepping motors device is ... heavy-duty durable shaker to provide a uniform ... in nature. Regulated action scale for all ... to control time, continuous time, action scale ...
Biology Products: